Monocyte-derived dendritic cell maturation and MHC class II expression (moDC maturation/MHCII)

Monocyte-derived dendritic cell (moDC) maturation and MHC class II expression represents a complex biological process rather than a single molecular target. This process involves the differentiation of blood monocytes into immature dendritic cells, which then undergo a profound phenotypic and functional transformation into mature, professional antigen-presenting cells upon stimulation by pathogens or inflammatory cytokines (Sallusto & Lanzavecchia, 1994). A hallmark of this maturation is the significant upregulation of Major Histocompatibility Complex (MHC) class II molecules (e.g., HLA-DR) and co-stimulatory molecules like CD80, CD83, and CD86, which are required for the activation of naive T cells (Roche & Furuta, 2015). In the context of disease, impaired moDC maturation is a common mechanism of immune evasion in cancer, while excessive or inappropriate maturation contributes to the pathogenesis of autoimmune and inflammatory diseases (Banchereau & Steinman, 1998). Pharmacological agents can either promote this process to enhance vaccine efficacy and anti-tumor immunity (e.g., TLR agonists) or inhibit it to treat transplant rejection and autoimmunity (e.g., corticosteroids or calcineurin inhibitors). Consequently, this process is frequently utilized as a primary endpoint in phenotypic drug screening and immunological research to assess the potency of immunomodulatory compounds.

Other names

moDC maturationMHC class II upregulation in dendritic cellsDendritic cell activationMonocyte-to-DC differentiation and maturation

Modulation of signaling pathways such as TLR, NF-kappaB, and JAK/STAT to influence dendritic cell activation and antigen presentation capacity.